Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
← catalyst calendarSponsored by Amneal Pharmaceuticals, LLC (industry) · AMRX — their whole pipeline →. With CBCC Global Research.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
168estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-29 | actual | When the study began enrolling |
| Primary completion | Dec 2022 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2022 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Glaucoma, Open-Angle
- Ocular Hypertension
Interventions
- Drug: Test - Bimatoprost 0.01% Ophthalmic Solution
- Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Primary outcome
what the primary-completion date above is the date OFMean difference in the intraocular pressure (IOP) of both eyes between the two treatment groups.
measured Day 14 and 42 at 00.00 hours, 04.00 hours, and 08.00 hours.
Permalink · AMRX's whole pipeline · Catalyst calendar · Every registered study · What changed